Abstract Oncogenic KRAS mutations occur in approximately 40% of colorectal cancer (CRC) cases and correlate with poor prognosis. While restoring GTP hydrolysis in KRAS-mutant tumors represents a promising therapeutic strategy, its mechanistic basis remains unclear. KRASQ25A mutant exhibits enhanced intrinsic GTPase activity, but its cellular impact is unknown. Here, we investigated the tumor-suppressive effects of KRASQ25A in KRASG12D-mutant CRC.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile